Plant-Based Oral Vaccines: Results of Human Trials

  • C. O. Tacket
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 332)

Vaccines consisting of transgenic plant-derived antigens offer a new strategy for development of safe, inexpensive vaccines. The vaccine antigens can be eaten with the edible part of the plant or purified from plant material. In phase 1 clinical studies of prototype potato- and corn-based vaccines, these vaccines have been safe and immunogenic without the need for a buffer or vehicle other than the plant cell. Transgenic plant technology is attractive for vaccine development because these vaccines are needle-less, stable, and easy to administer. This chapter examines some early human studies of oral transgenic plant-derived vaccines against enterotoxigenic Escherichia coli infection, norovirus, and hepatitis B.


Transgenic Plant Cholera Toxin Transgenic Potato Cholera Vaccine Norwalk Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arakawa T, Chong DK, Merritt JL, Langridge WH (1997) Expression of cholera toxin B subunit oligomers in transgenic potato plants. Transgenic Res 6:403–413PubMedCrossRefGoogle Scholar
  2. Arakawa T, Chong DK, Langridge WH (1998) Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat Biotechnol 16:292–297PubMedCrossRefGoogle Scholar
  3. Arakawa T, Yu J, Langridge WH (1999) Food plant-delivered cholera toxin B subunit for vaccination and immunotolerization. Adv Exp Med Biol 464:161–178PubMedGoogle Scholar
  4. Azhar AM, Singh S, Anand KP, Bhatnagar R (2002) Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem Biophys Res Commun 299:345–351CrossRefGoogle Scholar
  5. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK (1999) Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 117:40–48PubMedCrossRefGoogle Scholar
  6. Belanger H, Fleysh N, Cox S, et al (2000) Human respiratory syncytial virus vaccine antigen produced in plants. FASEB J 14:2323–2328PubMedCrossRefGoogle Scholar
  7. Beutels P (1998) Economic evaluations applied to HB vaccination: general observations. Vaccine 16 [Suppl:]S84–S92PubMedCrossRefGoogle Scholar
  8. Biemelt S, Sonnewald U, Galmbacher P, Willmitzer L, Muller M (2003) Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 77:9211–9220PubMedCrossRefGoogle Scholar
  9. Chargelegue D, Vine ND, van Dolleweerd CJ, Drake PM, Ma JK (2000) A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res 9:187–194PubMedCrossRefGoogle Scholar
  10. Chikwamba R, Cunnick J, Hathaway D, McMurray J, Mason H, Wang K (2002) A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res 11:479–493PubMedCrossRefGoogle Scholar
  11. Clemens JD, Sack DA, Harris JR, et al (1988) Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158:372–377PubMedGoogle Scholar
  12. Daniell H, Lee SB, Panchal T, Wiebe PO (2001a) Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J Mol Biol 311:1001–1009CrossRefGoogle Scholar
  13. Daniell H, Streatfield SJ, Wycoff K (2001b) Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci 6:219–226CrossRefGoogle Scholar
  14. Deneen VC, Hunt JM, Paule CR, et al (2000) The impact of foodborne calicivirus disease: the Minnesota experience. J Infect Dis 181 [Suppl 2]:S281–S283PubMedCrossRefGoogle Scholar
  15. Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM (2002) Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 20:1968–1974PubMedCrossRefGoogle Scholar
  16. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL (1999) Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18:449–459PubMedCrossRefGoogle Scholar
  17. Douce G, Giannelli V, Pizza M, et al (1999) Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect Immun 67:4400–4406PubMedGoogle Scholar
  18. Edelman R (1997) Adjuvants for the future. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS (eds) New generation vaccines. Marcel Dekker, New York, pp 173–192Google Scholar
  19. Fischer R, Hoffmann K, Schillberg S, Emans N (2000) Antibody production by molecular farming in plants. J Biol Regul Homeost Agents 14:83–92PubMedGoogle Scholar
  20. Gao Y, Ma Y, Li M, et al (2003) Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World J Gastroenterol 9:996–1002PubMedGoogle Scholar
  21. Giddings G (2001) Transgenic plants as protein factories. Curr Opin Biotechnol 12:450–454PubMedCrossRefGoogle Scholar
  22. Giddings G, Allison G, Brooks D, Carter A (2000) Transgenic plants as factories for biopharma-ceuticals. Nat Biotechnol 18:1151–1155PubMedCrossRefGoogle Scholar
  23. Glass RI, Noel J, Ando T, et al (2000) The epidemiology of enteric caliciviruses from humans: a reassessment using new diagnostics. J Infect Dis 181 [Suppl 2]:S254–S261PubMedCrossRefGoogle Scholar
  24. Grangette C, Muller-Alouf H, Geoffroy M, Goudercourt D, Turneer M, Mercenier A (2002) Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 20:3304–3309PubMedCrossRefGoogle Scholar
  25. Green K Y, Lew JF, Jiang X, Kapikian AZ, Estes MK (1993) Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol 31:2185–2191PubMedGoogle Scholar
  26. Haq TA, Mason HS, Clements JD, Arntzen CJ (1995) Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268:714–716PubMedCrossRefGoogle Scholar
  27. Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, Flynn P, Register J, Marshall L, Bond D, Kulisek E, Kusnadi A, Evangelista R, Nikolov Z, Wooge C, Mehigh RJ, Hernan R, Kappel WK, Ritland D, Li CP, Howard JA (1997) Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breed 3:291–306CrossRefGoogle Scholar
  28. Hood EE, Kusnadi A, Nikolov Z, Howard JA (1999) Molecular farming of industrial proteins from transgenic maize. Adv Exp Med Biol 464:127–147PubMedGoogle Scholar
  29. Huang Z, Dry I, Webster D, Strugnell R, Wesselingh S (2001) Plant-derived measles virus hemag-glutinin protein induces neutralizing antibodies in mice. Vaccine 19:2163–2171PubMedCrossRefGoogle Scholar
  30. Husby S, Mestecky J, Moldoveanu Z, Holland S, Elson CO (1994) Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol 152:4663–4670PubMedGoogle Scholar
  31. Jani D, Meena LS, Rizwan-ul-Haq QM, Singh Y, Sharma AK, Tyagi AK (2002) Expression of cholera toxin B subunit in transgenic tomato plants. Transgenic Res 11:447–454PubMedCrossRefGoogle Scholar
  32. Kapusta J, Modelska A, Figlerowicz M, et al (1999) A plant-derived edible vaccine against hepatitis B virus. FASEB J 13:1796–1799PubMedGoogle Scholar
  33. Kapusta J, Modelsak A, Pniewski T, et al (2001) Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv Exp Med Biol 495:299–303PubMedGoogle Scholar
  34. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y (2001) Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci U S A 98:11539–11544PubMedCrossRefGoogle Scholar
  35. Kusnadi AR, Evangelista RL, Hood EE, Howard JA, Nikolov ZL (1998a) Processing of transgenic corn seed and its effect on the recovery of recombinant beta-glucuronidase. Biotechnol Bioeng 60:44–52CrossRefGoogle Scholar
  36. Kusnadi AR, Hood EE, Witcher DR, Howard JA, Nikolov ZL (1998b) Production and purification of two recombinant proteins from transgenic corn. Biotechnol Prog 14:149–155CrossRefGoogle Scholar
  37. Lagos R, Kotloff K, Hoffenbach A, et al (1998) Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four-and six-month-old Chilean infants. Pediatr Infect Dis J 17:294–304PubMedCrossRefGoogle Scholar
  38. Lamphear BJ, Streatfield SJ, Jilka JM, et al (2002) Delivery of subunit vaccines in maize seed. J Control Release 85:169–180PubMedCrossRefGoogle Scholar
  39. Larrick JW, Thomas DW (2001) Producing proteins in transgenic plants and animals. Curr Opin Biotechnol 12:411–418PubMedCrossRefGoogle Scholar
  40. Lauterslager TG, Florack DE, van der Wal TJ, et al (2001) Oral immunisation of naive and primed animals with transgenic potato tubers expressing LT-B. Vaccine 19:2749–2755PubMedCrossRefGoogle Scholar
  41. Ma JK, Hiatt A, Hein M, et al (1995) Generation and assembly of secretory antibodies in plants. Science 268:716–719PubMedCrossRefGoogle Scholar
  42. Ma SW, Zhao DL, Yin ZQ, et al (1997) Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med 3:793–796PubMedCrossRefGoogle Scholar
  43. Ma JK, Hikmat B Y, Wycoff K, et al (1998) Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 4:601–606PubMedCrossRefGoogle Scholar
  44. Ma Y, Lin SQ, Gao Y, et al (2003) Expression of ORF2 partial gene of hepatitis E virus in tomatoes and immunoactivity of expression products. World J Gastroenterol 9:2211–2215PubMedGoogle Scholar
  45. Marquet-Blouin E, Bouche FB, Steinmetz A, Muller CP (2003) Neutralizing immunogenicity of trans-genic carrot (Daucus carota L)-derived measles virus hemagglutinin. Plant Mol Biol 51:459–469PubMedCrossRefGoogle Scholar
  46. Mason HS, Arntzen CJ (1995) Transgenic plants as vaccine production systems. Trends Biotechnol 13:388–392PubMedCrossRefGoogle Scholar
  47. Mason HS, Lam DM, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 89:11745–11749PubMedCrossRefGoogle Scholar
  48. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ (1996) Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 93:5335–5340PubMedCrossRefGoogle Scholar
  49. Mason HS, Haq TA, Clements JD, Arntzen CJ (1998) Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 16:1336–1343PubMedCrossRefGoogle Scholar
  50. Matsumura T, Itchoda N, Tsunemitsu H (2002) Production of immunogenic VP6 protein of bovine group A rotavirus in transgenic potato plants. Arch Virol 147:1263–1270PubMedCrossRefGoogle Scholar
  51. McGarvey PB, Hammond J, Dienelt MM, et al (1995) Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology (N Y) 13:1484–1487CrossRefGoogle Scholar
  52. Modelska A, Dietzschold B, Sleysh N, et al (1998) Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci U S A 95:2481–2485PubMedCrossRefGoogle Scholar
  53. Nardelli-Haefliger D, Kraehenbuhl JP, Curtiss R III, et al (1996) Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 64:5219–5224PubMedGoogle Scholar
  54. Orr N, Galen JE, Levine MM (1999) Expression and immunogenicity of a mutant diphtheria toxin molecule CRM(197), and its fragments in Salmonella typhi vaccine strain CVD 908-htrA. Infect Immun 67:4290–4294PubMedGoogle Scholar
  55. Pouwels PH, Leer RJ, Boersma WJ (1996) The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J Biotechnol 44:183–192PubMedCrossRefGoogle Scholar
  56. Richter LJ, Thanavala Y, Arntzen CJ, Mason HS (2000) Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nat Biotechnol 18:1167–1171PubMedCrossRefGoogle Scholar
  57. Rigano MM, Alvarez ML, Pinkhasov J, et al (2003) Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep 22:502–508PubMedCrossRefGoogle Scholar
  58. Ruf S, Hermann M, Berger IJ, Carrer H, Bock R (2001) Stable genetic transformation of tomato plastids and expression of a foreign protein in fruit. Nat Biotechnol 19:870–875PubMedCrossRefGoogle Scholar
  59. Sala F, Manuela RM, Barbante A, Basso B, Walmsley AM, Castiglione S (2003) Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine 21:803–808PubMedCrossRefGoogle Scholar
  60. Sandhu JS, Krasnyanski SF, Domier LL, Korban SS, Osadjan MD, Buetow DE (2000) Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response. Transgenic Res 9:127–135PubMedCrossRefGoogle Scholar
  61. Savarino SJ, Hall ER, Bassily S, et al (2002) Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 21:322–330PubMedCrossRefGoogle Scholar
  62. Scheppler L, Vogel M, Zuercher AW, et al (2002) Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine 20:2913–2920PubMedCrossRefGoogle Scholar
  63. Sciutto E, Fragoso G, Manoutcharian K, et al (2002) New approaches to improve a peptide vaccine against porcine Taenia solium cysticercosis. Arch Med Res 33:371–378PubMedCrossRefGoogle Scholar
  64. Smith G, Walmsley A, Polkinghorne I (1997) Plant-derived immunocontraceptive vaccines. Reprod Fertil Dev 9:85–89PubMedCrossRefGoogle Scholar
  65. Smith ML, Mason HS, Shuler ML (2002) Hepatitis B surface antigen (HBsAg) expression in plant cell culture: kinetics of antigen accumulation in batch culture and its intracellular form. Biotechnol Bioeng 80:812–822PubMedCrossRefGoogle Scholar
  66. Stein KE, Webber KO (2001) The regulation of biologic products derived from bioengineered plants. Curr Opin Biotechnol 12:308–311PubMedCrossRefGoogle Scholar
  67. Stokstad E, Vogel G (2003) Agrobiotechnology. Mixed message could prove costly for GM crops. Science 302:542–543Google Scholar
  68. Streatfield SJ, Jilka JM, Hood EE, et al (2001) Plant-based vaccines: unique advantages. Vaccine 19:2742–2748PubMedCrossRefGoogle Scholar
  69. Streatfield SJ, Mayor JM, Barker DK, Brooks C, Lamphear BJ, Woodard SL, Beifuss KK, Vicuna DV, Massey LA, Horn ME, Delaney DD, Nikoov ZL, Hood EE, Jilka JM, Howard JA (2002) Development of an edible subunit vaccine in corn against enterotoxigenic strains of Escherichia coli. In Vitro Cell Dev Biol Plant 38:11–17CrossRefGoogle Scholar
  70. Streatfield SJ, Lane JR, Brooks CA, et al (2003) Corn as a production system for human and animal vaccines. Vaccine 21:812–815PubMedCrossRefGoogle Scholar
  71. Strober W, Kelsall B, Marth T (1998) Oral tolerance. J Clin Immunol 18:1–30PubMedCrossRefGoogle Scholar
  72. Tackaberry ES, Dudani AK, Prior F, et al (1999) Development of biopharmaceuticals in plant expression systems: cloning, expression and immunological reactivity of human cytomegalo- virus glycoprotein B (UL55) in seeds of transgenic tobacco. Vaccine 17:3020–3029PubMedCrossRefGoogle Scholar
  73. Tackaberry ES, Prior F, Bell M, et al (2003) Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Genome 46:521–526PubMedCrossRefGoogle Scholar
  74. Tacket CO, Kelly SM, Schodel F, et al (1997) Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun 65:3381–3385PubMedGoogle Scholar
  75. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ (1998) Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 4:607–609PubMedCrossRefGoogle Scholar
  76. Tacket CO, Galen J, Sztein MB, et al (2000a) Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 97:146–153CrossRefGoogle Scholar
  77. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ (2000b) Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 182:302–305CrossRefGoogle Scholar
  78. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK (2003) Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 108:241–247PubMedCrossRefGoogle Scholar
  79. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S (2004) Immunogenicity of recom-binant LT-B delivered orally to humans in transgenic corn. Vaccine 22:4385–4389PubMedCrossRefGoogle Scholar
  80. Thanavala Y, Yang YF, Lyons P, Mason HS, Arntzen C (1995) Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc Natl Acad Sci U S A 92:3358–3361PubMedCrossRefGoogle Scholar
  81. Vieira da Silva J, Garcia AB, Vieira Flores VM, Sousa de Macedo Z, Medina-Acosta E (2002) Phytosecretion of enteropathogenic Escherichia coli pilin subunit A in transgenic tobacco and its suitability for early life vaccinology. Vaccine 20:2091–2101CrossRefGoogle Scholar
  82. Walmsley AM, Alvarez ML, Jin Y, et al (2003) Expression of the B subunit of Escherichia coli heat-labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep 21:1020–1026PubMedCrossRefGoogle Scholar
  83. Warzecha H, Mason HS, Lane C, et al (2003) Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 77:8702–8711PubMedCrossRefGoogle Scholar
  84. Webster DE, Cooney ML, Huang Z, et al (2002a) Successful boosting of a DNA measles immunization with an oral plant-derived measles virus vaccine. J Virol 76:7910–7912CrossRefGoogle Scholar
  85. Webster DE, Thomas MC, Strugnell RA, Dry IB, Wesselingh SL (2002b) Appetising solutions: an edible vaccine for measles. Med J Aust 176:434–437Google Scholar
  86. Woodard SL, Mayor JM, Bailey MR, et al (2003) Maize (Zea mays)-derived bovine trypsin: characterization of the first large-scale, commercial protein product from transgenic plants. Biotechnol Appl Biochem 38:123–130PubMedCrossRefGoogle Scholar
  87. Xi JN, Graham DY, Wang KN, Estes MK (1990) Norwalk virus genome cloning and characterization. Science 250:1580–1583PubMedCrossRefGoogle Scholar
  88. Yu J, Langridge WH (2001) A plant-based multicomponent vaccine protects mice from enteric diseases. Nat Biotechnol 19:548–552PubMedCrossRefGoogle Scholar
  89. Yusibov V, Hooper DC, Spitsin S V, et al (2002) Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20:3155–3164PubMedCrossRefGoogle Scholar
  90. Zambryski P (1988) Basic processes underlying Agrobacterium-mediated DNA transfer to plant cells. Annu Rev Genet 22:1–30PubMedCrossRefGoogle Scholar
  91. Zegers ND, Kluter E, van Der SH, et al (1999) Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol 87:309–314PubMedCrossRefGoogle Scholar
  92. Zeitlin L, Olmsted SS, Moench TR, et al (1998) A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol 16:1361–1364PubMedCrossRefGoogle Scholar
  93. Zhang GG, Rodrigues L, Rovinski B, White KA (2002) Production of HIV-1 p24 protein in trans-genic tobacco plants. Mol Biotechnol 20:131–136PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • C. O. Tacket
    • 1
  1. 1.Center for Vaccine DevelopmentUniversity of Maryland School of MedicineBaltimore

Personalised recommendations